Race Oncology (ASX: RAC) – Zantrene’s Role As An FTO Inhibitor To Cure Cancer Globally

TL;DR

Race Oncology has made significant advancements in the FTO space with their drug Xantrine, which has shown promising results in treating melanoma, opening up possibilities for a wide range of cancers.

Transcript

hey guys and welcome back to the asx investor channel and welcome to another interview today we will be revisiting the race oncology story asx rac is a fascinating company we've discussed them in detail before and today we're very excited to be welcoming back to the channel dr daniel tillett he's the chief scientific officer an executive director o... Read More

Key Insights

• 🎁 FTO inhibition with Xantrine presents a unique opportunity in precision oncology, as it can potentially target multiple cancer types that overexpress FTO.
• 👾 Xantrine's impressive sensitivity in melanoma cells that overexpress FTO demonstrates its potential as a game-changing treatment for metastatic melanoma.
• ♋ The ability of Xantrine to overcome drug resistance and sensitize cancer cells to other therapies opens up new avenues in cancer treatment.
• 💋 Race Oncology's focus on FTO inhibition marks a significant shift from traditional chemotherapeutic approaches, positioning them at the forefront of groundbreaking cancer research.
• ♋ Xantrine not only has the potential to transform patient outcomes but offers a commercial opportunity due to its broad spectrum of cancer indications.
• 🦔 Investing in Race Oncology provides an opportunity for individual investors to gain an edge over institutional investors, considering the relatively untapped potential of FTO inhibition in the market.
• 🧘 Xantrine's clinical data, once available, is expected to further solidify its position as a viable and highly promising treatment option, potentially attracting interest from pharmaceutical companies and accelerating Race Oncology's growth.

Questions & Answers

Q: How did Xantrine become a leading FTO inhibitor for cancer treatment?

Xantrine's success as an FTO inhibitor stems from its discovery during a screening study conducted by the City of Hope, identifying it as the most potent and best-in-class drug in its class. It was fortuitously present in the National Cancer Institute's library and showed tremendous potential in inhibiting FTO's role in cancer development.

Q: What makes FTO inhibition a significant breakthrough in cancer treatment?

FTO inhibition targets two challenging aspects of cancer: metastasis and drug resistance. Metastasis, the spread of cancer throughout the body, and the development of resistance to cancer drugs are interrelated processes. By inhibiting FTO, Xantrine can potentially thwart both processes, offering a promising approach in cancer treatment.

Q: In addition to treating melanoma, what other types of cancers can Xantrine potentially target?

FTO expression has been observed in various cancer types, presenting an opportunity for Xantrine to target a wide range of cancers. Studies have shown that at least 25 different cancers overexpress FTO, indicating its potential effectiveness across multiple indications, including renal cell clear cell carcinoma and acute myeloid leukemia.

Q: How does Xantrine overcome drug resistance when combined with other cancer treatments?

Xantrine's ability to sensitize cancer cells to other drugs, such as immune checkpoint inhibitors, is a critical finding. When FTO is inhibited, cancer cells that were previously resistant to these drugs regain sensitivity. This combination potential increases the effectiveness of existing treatments and offers hope for patients who do not respond to current therapies.

Summary & Key Takeaways

• Race Oncology's drug Xantrine, the most potent FTO inhibitor available, has shown impressive results in inhibiting the protein FTO, which is crucial in the development of cancer and its spread.

• Xantrine has demonstrated significant sensitivity in melanoma cells that overexpress FTO, making it a potential game-changer in treating metastatic melanoma and overcoming drug resistance.

• FTO inhibition offers a unique opportunity for precision oncology, as it is found to be overexpressed in several cancers, making Xantrine potentially effective against a wide range of cancer types.